Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
Follow JNJ
Alert me
Johnson & Johnson (JNJ) Book value per share
Johnson & Johnson's book value per share at the end of fiscal 2025 was 33.9×, up 14.1% from 29.7× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 33.8×. Over the past ten years it has ranged from 22.3× (fiscal 2018) to 33.9× (fiscal 2025) — the current reading is the highest in ten years. Johnson & Johnson ranks 4th of 21 Drug Manufacturers General companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 33.9× | 14.06% |
| FY2024 | 29.7× | 9.40% |
| FY2023 | 27.1× | (7.21%) |
| FY2022 | 29.3× | 4.03% |
| FY2021 | 28.1× | 17.01% |
| FY2020 | 24.0× | 6.90% |
| FY2019 | 22.5× | 0.90% |
| FY2018 | 22.3× | (0.29%) |
| FY2017 | 22.3× | (13.13%) |
| FY2016 | 25.7× | 0.22% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 33.8× | (4.14%) |
| Jun 2026 | 35.3× | 4.72% |
| Mar 2026 | 33.7× | (0.49%) |
| Dec 2025 | 33.9× | 2.90% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| LLY Eli Lilly and Company compare | 45.2× |
| JNJ Johnson & Johnson | 33.8× |
| AZN AstraZeneca PLC compare | 33.4× |
| AMGN Amgen Inc. compare | 26.5× |
| NVS Novartis AG compare | 19.8× |
| MRK Merck & Co., Inc. compare | 17.0× |
| PFE Pfizer Inc. compare | 15.7× |
| GILD Gilead Sciences, Inc. compare | 10.4× |
| ABBV AbbVie Inc. compare | −2.6× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement